In conclusion, in the systematic review of ICI studies in MSS CRC, we observed that the ICI monotherapy was significantly limited in efficacy, while the combinations with anti-VEGF TKI, other immune-modulatory agents and BRAF inhibitors may have more efficacy. Here, VEGFA is linked to colorectal carcinoma.